“The current predicament has uncovered some structural weaknesses from the EU’s medicines offer chain and also a significant dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides said. She encouraged that supply chain problems be resolved in an EU pharmaceutical tactic envisioned for being released by the tip of the https://www.rilife.co/products/